A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Registration Number
- NCT00367445
- Lead Sponsor
- Pfizer
- Brief Summary
To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Diabetes mellitus Type 2
Read More
Exclusion Criteria
- Severe Asthma, severe COPD
- Smoking
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Variability of blood glucose over a period of 72 hours
- Secondary Outcome Measures
Name Time Method Insulin pharmacokinetics
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇺🇸Chula Vista, California, United States